SCHEMBL735202

SCHEMBL735202

CN1CCN(c2ccccc2F)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
ADRA2C P18825 1/20 0.60
HSD17B10 Q99714 1/20 0.59
DRD3 P35462 3/20 0.56
DRD2 P14416 2/20 0.56
KDM4E B2RXH2 4/20 0.56
TSHR P16473 3/20 0.56
POLB P06746 1/20 0.56
TDP1 Q9NUW8 1/20 0.54
ALOX15 P16050 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
DRD4 P21917 1/20 0.53
GLA P06280 1/20 0.53
MEN1 O00255 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717743 0.93 NCF1 (0.59) ALDH1A1SMN1; SMN2ADRA2CHSD17B10DRD3
SCHEMBL13382891 0.84 DRD2 (0.53) ALDH1A1SMN1; SMN2ADRA2CHSD17B10DRD3
SCHEMBL23161511 0.80 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2HSD17B10DRD3KDM4E
SCHEMBL3042980 0.80 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HSD17B10KDM4ETSHR
SCHEMBL21361444 0.79 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2HSD17B10DRD3KDM4E
SCHEMBL1372296 0.79 SMN1; SMN2 (0.59) ALDH1A1SMN1; SMN2HSD17B10KDM4ETSHR
SCHEMBL8044642 0.79 KDM4E (0.65) ALDH1A1SMN1; SMN2HSD17B10DRD3DRD2
SCHEMBL8981965 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HSD17B10KDM4ETSHR
SCHEMBL13898854 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HSD17B10KDM4ETSHR
SCHEMBL12631522 0.79 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2HSD17B10KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861605-B1 6-Benzyl-6H-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one derivatives as phosphodiesterase-1 (PDE-1) inhibitors for the treatment of e.g. neurological, cognitive and cardiovascular disorders DART NEUROSCIENCE (CAYMAN) LTD (KY) 2017-05-03 EP claimed
US-9499562-B2 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2016-11-22 US claimed
US-20160031901-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS DART NEUROSCIENCE LLC 2016-02-04 US claimed
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 US disclosed
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 US disclosed
US-20230015617-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2023-01-19 US disclosed
EP-4112614-A1 GLUTARIMIDE SKELETON-BASED COMPOUNDS AND APPLICATION THEREOF Shanghaitech University (CN) 2023-01-04 EP disclosed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 US disclosed
US-11160803-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2021-11-02 US disclosed
WO-2020259683-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF 成都赜灵生物医药科技有限公司 2020-12-30 WO disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 US disclosed
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed
EP-1833800-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2007-09-19 EP disclosed
US-7238695-B2 Imidazolyl derivatives SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) 2007-07-03 US disclosed
US-7220765-B2 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) 2007-05-22 US disclosed
US-20070105861-A1 NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS GRUENENTHAL GMBH (DE) 2007-05-10 US disclosed
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use IPSEN PHARMA S.A.S. (FR) 2007-02-22 US disclosed
WO-2006071730-A1 PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2006-07-06 WO disclosed
US-5945421-A TREATING PSYCHOSIS AND SCHIZOPHRENIA WARNER-LAMBERT COMPANY (US) 1999-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods IL2, IL4, IRF3 ALDH1A1 2134/4885SMN1; SMN2 3807/4885ADRA2C 570/4885
US-20070105861-A1 NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS TRPV1, TRPV5, TRPV2 ALDH1A1 2444/4885SMN1; SMN2 4541/4885ADRA2C 106/4885
US-11160803-B2 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 ALDH1A1 1678/4885SMN1; SMN2 3730/4885ADRA2C 1228/4885
US-20160031901-A1 SUBSTITUTED THIOPHENE- AND FURAN-FUSED AZOLOPYRIMIDINE-5-(6H)-ONE COMPOUNDS TPMT, PSEN2, GRIN2C ALDH1A1 405/4885SMN1; SMN2 132/4885ADRA2C 1900/4885
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR PARP3, PARP1, PARP4 ALDH1A1 1311/4885SMN1; SMN2 4242/4885ADRA2C 4715/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 ALDH1A1 1361/4885SMN1; SMN2 3418/4885ADRA2C 2739/4885
US-20070043095-A1 Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use SSTR2, SSTR5, SSTR3 ALDH1A1 812/4885SMN1; SMN2 1973/4885ADRA2C 50/4885
US-20230015617-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 ALDH1A1 1599/4885SMN1; SMN2 3650/4885ADRA2C 1112/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 ALDH1A1 1361/4885SMN1; SMN2 3418/4885ADRA2C 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.